Book a Meeting

Fc Engineered Anti-Human SLAMF7 Therapeutic Antibody, a CDC-Enhanced Biobetter [Lot: CB20-PZ25] (CAT#: BioBet-C025ZP) Datasheet

Target
SLAMF7
Isotype
Whole Humanized Antibody
Description
CDC-enhanced Elotuzumab is a Fc-modified anti-SLAMF7 therapeutic biobetter. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Elotuzumab, the Fc region of Elotuzumab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
Indication
Refractory Multiple Myeloma
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Elotuzumab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
SLAMF7
Full Name
SLAM family member 7
Alternative Names
19A; CS1; CD319; CRACC
Gene ID
57823
UniProt ID
Q9NQ25
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
Humanized IgG1; ADC
Description
Elotuzumab is a humanized monoclonal antibody for relapsed multiple myeloma. Elotuzumab is produced in NS0 cells by recombinant DNA technology and targets SLAMF7. On November 30, 2015, Elotuzumab was approved by the US Food and Drug Administration.
Indication
Refractory Multiple Myeloma
Synonyms
HuLuc63

Elotuzumab is a humanized IgG1 monoclonal antibody that specifically binds the SLAMF7 protein. SLAMF7 is a member of the signaling lymphocyte activation molecule family and is expressed on myeloma cells. Studies have shown that Elotuzumab directly activates natural killer cells through the SLAMF7 pathway and Fc receptors, further promotes interaction with Natural Killer cells through antibody-dependent cytotoxicity (ADCC), and mediates killing of myeloma cells.

Refractory Multiple Myeloma

Related Products

Fc Engineered Anti-Human SLAMF7 Therapeutic Antibody, a CDC-Enhanced Biobetter [Lot: CB20-PZ442] (CAT#: Biobet-C442ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany